91 related articles for article (PubMed ID: 9826447)
1. Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses.
Vogel K; Kantor J; Wood L; Rivera R; Schlom J
Cell Immunol; 1998 Nov; 190(1):61-7. PubMed ID: 9826447
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
3. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
Ke Y; Kapp JA
J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
[TBL] [Abstract][Full Text] [Related]
4. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
5. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
[TBL] [Abstract][Full Text] [Related]
6. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
Wang W; Golding B
Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
[TBL] [Abstract][Full Text] [Related]
7. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen.
Jain SL; Barone KS; Michael JG
Cell Immunol; 1996 Feb; 167(2):170-5. PubMed ID: 8603425
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T-cell tolerance induced by delivery of antigen to the anterior chamber is not the result of de facto intravenous or mucosal administration of antigen.
McKenna KC; Anderson KM; Kapp JA
Ocul Immunol Inflamm; 2005; 13(2-3):149-57. PubMed ID: 16019674
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
10. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
[TBL] [Abstract][Full Text] [Related]
11. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
12. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
13. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
14. In vivo CTL immunity can be elicited by OVA-linker-beta2m fusion protein.
Qian L; Qian GX
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Sep; 34(5):547-52. PubMed ID: 12198554
[TBL] [Abstract][Full Text] [Related]
15. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
17. Gammadelta T cells in anterior chamber-induced tolerance in CD8(+) CTL responses.
Xu Y; Kapp JA
Invest Ophthalmol Vis Sci; 2002 Nov; 43(11):3473-9. PubMed ID: 12407158
[TBL] [Abstract][Full Text] [Related]
18. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
[TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
20. Investigation of antigen delivery route in vivo and imune-boosting effects mediated by pH-sensitive liposomes encapsulated with K(b)-restricted CTL epitope.
Lee KY; Chun E; Seong BL
Biochem Biophys Res Commun; 2002 Apr; 292(3):682-8. PubMed ID: 11922620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
